Testing two medicines for active systemic juvenile arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and under 18 years old (in some countries where the shot is not approved).
- You have active sJIA for at least 6 weeks, with symptoms starting before age 16.
- You have ongoing signs of active disease: at least 2 active joints (and fever) or at least 4 active joints, plus blood inflammation markers above normal.
- You tried anti-inflammatory medicines like NSAIDs and/or steroids, but they were not enough or not tolerated.
- Depending on the trial group: you either have not taken an IL-6 inhibitor before, or you could not tolerate or respond well to an IL-6 inhibitor.
- You do not have other types of juvenile arthritis or other autoimmune inflammatory diseases besides sJIA.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
This trial tests a new medicine called olokizumab in children and teenagers with juvenile idiopathic arthritis (JIA)—a condition where the immune system causes joint inflammation and pain. The study checks if this drug is safe and effective for children whose arthritis hasn't improved enough with standard treatments.
This study tests baricitinib, a medicine, in children and teens with juvenile idiopathic arthritis. It includes only families who already took baricitinib in an earlier study and did not stop it permanently or develop an allergy.
This Phase 3 study tests whether children with early juvenile idiopathic arthritis do better by starting with one treatment approach and adjusting (stepping up or stepping down) based on how their arthritis responds. It may help find the safest, most effective long-term plan for controlling symptoms with fewer side effects.
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.